Dr. Kaeberlein's Optispan Podcast Series - Rapamycin and More

Key Takeaways

• Human equivalent dose estimated at 1.1 g daily for 70 kg adult
• Bone mineral density loss identified as primary safety barrier
• Monthly cost exceeds $40,000, making human trials financially prohibitive
• Biomarker panel includes SREBP-2 reduction and HO‑1 induction
• Combining 3HAA with SGLT2 inhibitors raises fracture risk

Pulse Analysis

The kynurenine pathway metabolite 3‑hydroxyanthranilic acid (3HAA) has emerged from mouse longevity studies as a potential metabolic master‑switch, activating NRF2, FOXO and FMO2 pathways. While preclinical data show improved liver health and reduced atherosclerosis, the translational leap to humans is hampered by pharmacokinetic uncertainties. Oral bioavailability is low, the compound’s half‑life is fleeting, and its redox‑active nature can generate reactive oxygen species in the presence of metals, raising concerns about DNA damage and bone health. These mechanistic nuances underscore why dosing strategies derived from body‑surface‑area scaling—approximately 1.1 g per day for a 70‑kg adult—remain theoretical without human safety data.

Safety considerations dominate the discussion. Chronic elevation of 3HAA in mice improves hepatic markers but also impairs osteoblast differentiation, leading to measurable bone mineral density loss. Moreover, 3HAA is a precursor to quinolinic acid, a potent neurotoxin, though HAAO inhibition may paradoxically reduce quinolinic acid formation. The absence of a defined NOAEL or LD50 for humans, combined with reports of pro‑oxidant damage at high concentrations, makes regulatory approval unlikely without extensive toxicology studies. Biomarker verification—such as reduced hepatic SREBP‑2 mRNA and increased plasma 3HAA:anthranilic‑acid ratios—offers a measurable readout, yet translating these signals into clinical endpoints will require rigorous human trials.

Economic feasibility presents an equally formidable hurdle. At current research‑chemical pricing of roughly $1,390 per gram, a daily HED translates to over $40,000 per month, far beyond the budget of most clinical programs. Even bulk sourcing cannot bring costs below several hundred dollars monthly, making large‑scale human studies prohibitive without a clear efficacy signal. Interaction profiles add another layer of complexity: while metformin poses low risk, combining 3HAA with SGLT2 inhibitors could exacerbate bone fragility, a concern for aging populations. Until safety, cost, and efficacy gaps are bridged, 3HAA remains a promising yet speculative addition to the longevity stack.